Zhejiang Wolwo Bio-Pharma Gains 94% Post-IPO

January 24, 2014 -- Zhejiang Wolwo Bio-Pharmaceutical completed a very successful IPO this week, a 506 million RMB ($83.7 million) transaction that listed the company on the Shenzhen exchange. It was one of eight China companies to become publicly owned after China shut down the IPO process for 14 months. Regulators revamped the country’s IPO process to make it more market oriented. Wolwo finished the week with a strong 94% gain. After pricing at 20.05 RMB, it climbed to 38.81 RMB. More details....